Brief: Galecto Says GB2064 Shows Reduction In Fibrosis Of Bone Marrow In Patients With Myelofibrosis, Validating LOXL2 As A Clinical Fibrosis Target

Damora Therapeutics

29/09/2022 11:04

Sept 29 (Reuters) - Galecto Inc  GLTO.O :
    * GB2064 SHOWS REDUCTION IN FIBROSIS OF THE BONE MARROW IN
PATIENTS WITH MYELOFIBROSIS, VALIDATING LOXL2 AS A CLINICAL
FIBROSIS TARGET
    * GALECTO - 4 OUT OF 5 MYELOFIBROSIS PATIENTS WHO GOT GB2064
MONOTHERAPY FOR AT LEAST 6 MONTHS IN MYLOX-1 TRIAL EXPERIENCED ≥
1-GRADE REDUCTION IN COLLAGEN FIBROSIS
    * GALECTO INC - GB2064 HAS SHOWN A GENERALLY ACCEPTABLE
TOLERABILITY PROFILE TO DATE
    * GALECTO INC - IN FIVE PATIENTS WHO COMPLETED AT LEAST SIX
MONTHS
OF TREATMENT WITH GB2064, THERE WERE NO TREATMENT-RELATED
SERIOUS ADVERSE EVENTS

Source text for Eikon:  ID:nGNX7TQ7vx 
Further company coverage:  GLTO.O 
 ((Reuters.Briefs@thomsonreuters.com;;))